The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 901–1,000 of 1,005
Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations
Hesterberg, A. B., Gordetsky, J., & Hurley, P. J. (2021) · Urology · doi:10.1016/j.urology.2021.05.028 · Cited by 35
Bai, B., Chen, Q., Jing, R., He, X., Wang, H., Ban, Y., Qi, Y., Xu, W., & Zheng, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.738235 · Cited by 35
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos, P., Mullenders, J., Trimarchi, T., & Aifantis, I. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00001-3 · Cited by 37
Histone H2A.Z deregulation in prostate cancer. Cause or effect?
Dryhurst, D. D., & Ausió, J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9486-9 · Cited by 37
Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and OpportunitiesPreprint
Trabzonlu, L., Kulaç, İ., Zheng, Q., Hicks, J. L., Haffner, M. C., Nelson, W. G., Sfanos, K. S., Ertunç, O., Lotan, T. L., Heaphy, C. M., et al. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030403 · Cited by 36
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer
Kluth, M., Ahrary, R., Hube‐Magg, C., Ahmed, M. W., Volta, H., Schwemin, C., Steurer, S. A., Wittmer, C., Wilczak, W., Burandt, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4626 · Cited by 34
Song, Z., Cao, Q., Guo, B., Ye, Z., Li, X., Lou, N., Zhu, C., Luo, G., Peng, S., Li, G., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0202 · Cited by 34
Wang, L., Williamson, S. R., Zhang, S., Huang, J., Montironi, R., Davison, D. D., Wang, M., Yao, J. L., Antonio Lopez-beltran, B., Osunkoya, A. O., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22162 · Cited by 34
Immunotherapy for prostate cancer: False promises or true hope?
Rekoske, B. T., & McNeel, D. G. (2016) · Cancer · doi:10.1002/cncr.30250 · Cited by 35
HOXC6 promotes cervical cancer progression via regulation of Bcl‐2
Wang, Y., Wang, C., Liu, N., Hou, J., Xiao, W., & Wang, H. (2018) · The FASEB Journal · doi:10.1096/fj.201801099rr · Cited by 34
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers
Stelloo, S., Bergman, A. M., & Zwart, W. T. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0032 · Cited by 37
Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2
Sarkar, P. L., Lee, W., Williams, E. D., Lubik, A. A., Stylianou, N., Shokoohmand, A., Lehman, M., Hollier, B. G., Gunter, J. H., & Nelson, C. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00481 · Cited by 35
Distinct Genomic Alterations in Prostate Tumors Derived from African American Men
Liu, W., Zheng, S. L., Na, R., Wei, L., Sun, J., Gallagher, J., Wei, J., Resurreccion, W. K., Ernst, S., Sfanos, K. S., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0648 · Cited by 34
G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
Mukhopadhyay, C., Yang, C., Xu, L., Liu, D., Wang, Y., Huang, D., Deonarine, L. D., Cyrta, J., Davicioni, E., Sboner, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27024-x · Cited by 35
Self-citationBambury, R. M., & Rathkopf, D. E. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.025 · Cited by 35
Varışlı, L. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0524 · Cited by 34
Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line
Alves, I. T., Hiltemann, S., Hartjes, T. A., van der Spek, P. J., Stubbs, A., Trapman, J., & Jenster, G. W. (2013) · Human Genetics · doi:10.1007/s00439-013-1308-1 · Cited by 34
Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells
Recouvreux, M. V., Wu, B. J., Gao, A. C., Zonis, S., Chesnokova, V., Bhowmick, N. A., Chung, L. W. K., & Melmed, S. K. (2017) · Endocrinology · doi:10.1210/en.2016-1939 · Cited by 35
UTX Regulates Human Neural Differentiation and Dendritic Morphology by Resolving Bivalent Promoters
Tang, Q.-Y., Zhang, S.-F., Dai, S., Liu, C., Wang, Y.-Y., Du, H.-Z., Teng, Z., & Liu, C. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.06.015 · Cited by 35
Anselmino, N., Labanca, E., Shepherd, P. D. A., Dong, J., Yang, J., Song, X., Nandakumar, S., Kundra, R., Lee, C. J., Schultz, N. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2438 · Cited by 33
Gururajan, M., Cavassani, K. A., Sievert, M. F., Duan, P., Lichterman, J. N., Huang, J.-M., Smith, B., You, S., Nandana, S., Chu, G. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6398 · Cited by 33
Focal therapy in prostate cancer: A review of seven common controversies
Bass, E. J., & Ahmed, H. U. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.004 · Cited by 33
Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients
Wang, C., Shahi, P., Huang, J., Phan, N. N., Sun, Z., Lin, Y.-C., Lai, M., & Werb, Z. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1094 · Cited by 33
Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer
Xie, M., Xie, R., Xie, S., Wu, Y., Wang, W., Li, X., Xu, Y., Liu, B., Zhou, Y., Wang, T., et al. (2020) · Cell Biology International · doi:10.1002/cbin.11418 · Cited by 33
Self-citationGilson, C., Ingleby, F. C., Gilbert, D. C., Parry, M., Atako, N. B., Ali, A., Hoyle, A. P., Clarke, N. W., Gannon, M. R., Wanstall, C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00388 · Cited by 34
Jun, A., Zhang, B., Zhang, Z., Hu, H., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13040917 · Cited by 33
Interpreting new molecular genetics in myelodysplastic syndromes
Abdel-Wahab, O. I., & Figueroa, M. E. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.56.3798194 · Cited by 33
Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting
Pejcic, T. P., Todorović, Z., Đurašević, S., & POPOVIC, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032939 · Cited by 37
8p deletion is strongly linked to poor prognosis in breast cancer
Lebok, P., Mittenzwei, A., Kluth, M., Oezden, C., Taskin, B., Hussein, K., Möller, K., Hartmann, A., Lebeau, A., Witzel, I., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046025 · Cited by 33
Gelman, I. H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8264 · Cited by 35
Wu, M., Wang, X., McGregor, N., Pienta, K. J., & Zhang, J. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.090688 · Cited by 33
Self-citationROS-independent Nrf2 activation in prostate cancer
Bellezza, I., Scarpelli, P. T., Pizzo, S. V., Grottelli, S., Costanzi, E., & Minelli, A. (2017) · Oncotarget · doi:10.18632/oncotarget.18724 · Cited by 33
Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer
Wang, Z., Wu, D., Ng, C., Teoh, J. Y., Yu, S., Wang, Y., & Chan, F. L. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0280 · Cited by 33
SIRT1 contributes to neuroendocrine differentiation of prostate cancer
Ruan, L., Wang, L., Wang, X., He, M., & Yao, X. (2017) · Oncotarget · doi:10.18632/oncotarget.23111 · Cited by 33
TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways
Ye, J., Chu, C., Chen, M., Shi, Z., Gan, S., Qu, F., Pan, X., Yang, Q., Tian, Y., Wang, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6854 · Cited by 33
New CDK8 inhibitors as potential anti-leukemic agents – Design, synthesis and biological evaluation
Solum, E. J., Hansen, T. V., Aesöy, R., & Herfindal, L. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115461 · Cited by 33
Does the microenvironment influence the cell types of origin for prostate cancer?Preprint
Goldstein, A. S., & Witte, O. N. (2013) · Genes & Development · doi:10.1101/gad.222380.113 · Cited by 34
Role of formin INF2 in human diseases
Zhao, Y., Zhang, H., Wang, H., Ye, M., & Jin, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06869-x · Cited by 32
CHD1, a multifaceted epigenetic remodeler in prostate cancer
Li, H., Gigi, L., & Zhao, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1123362 · Cited by 33
The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer
Zhang, Y., Zhang, Q., Zhang, Y., & Han, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054939 · Cited by 37
Alternative splicing in prostate cancer progression and therapeutic resistance
Rawat, C., & Heemers, H. V. (2024) · Oncogene · doi:10.1038/s41388-024-03036-x · Cited by 32
Shrestha, R., Chesner, L. N., Zhang, M., Zhou, S., Foye, A., Lundberg, A., Weinstein, A. S., Sjöström, M., Zhu, X., Moreno-Rodriguez, T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0890 · Cited by 34
Venetis, K., Frascarelli, C., Bielo, L. B., Cursano, G., Adorisio, R., Ivanova, M. D., Mane, E., Peruzzo, V., Concardi, A., Negrelli, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115233 · Cited by 34
Guo, J., Liu, X., & Wang, M. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.127 · Cited by 32
Tian, X., He, Y., & Zhou, J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00057 · Cited by 32
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis
Ray, M., Goldstein, S., Zhou, S., Potamousis, K. D., Sarkar, D., Newton, M. A., Esterberg, E. J., Kendziorski, C. M., Bögler, O., & Schwartz, D. C. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-505 · Cited by 32
Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies
Dorn, J., Bayani, J., Yousef, G. M., Yang, F., Magdolen, V., Kiechle, M. B., Diamandis, E. P., & Schmitt, M. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-03-0206 · Cited by 32
Wanjala, J., Taylor, B. S., Chapinski, C., Hieronymus, H., Wongvipat, J., Chen, Y., Nanjangud, G. J., Schultz, N. D., Xie, Y., Liu, S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0542-t · Cited by 32
Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Zhang, W., Yi, B., Wang, C., Chen, D., Bae, S., Wei, S., Guo, R., Lu, C., Nguyen, L. L. H., Yang, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1927 · Cited by 32
Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation
Sung, H., Kanchi, K., Wang, X., Hill, K. S., Messina, J. L., Lee, J., Kim, Y., Dees, N. D., Ding, L., Teer, J. K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8127 · Cited by 34
Seed, G., Yuan, W., Mateo, J., Carreira, S., Bertan, C. M., Lambros, M. B. K., Boysen, G., Ferraldeschi, R., Miranda, S., Figueiredo, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0972 · Cited by 32
Self-citationThe androgen receptor malignancy shift in prostate cancer
Copeland, B. T., Pal, S. K., Bolton, E. C., & Jones, J. O. (2018) · The Prostate · doi:10.1002/pros.23497 · Cited by 32
Oliveira, D. M., Laudanna, C., Migliozzi, S., Zoppoli, P., Santamaria, G., Grillone, K., Elia, L., Mignogna, C., Biamonte, F., Sacco, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25251 · Cited by 32
Lin, C., Jan, Y., Kuo, L., Wang, B., Huo, C., Jiang, S. S., Chen, S., Kuo, Y., Chang, C., & Chuu, C. (2018) · Cancer Science · doi:10.1111/cas.13776 · Cited by 32
Nerlakanti, N., Yao, J., Nguyen, D. T., Patel, A. K., Eroshkin, A. M., Lawrence, H. R., Ayaz, M., Kuenzi, B. M., Agarwal, N., Chen, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0602 · Cited by 32
Yao, J., Chen, Y., Nguyen, D. T., Thompson, Z., Eroshkin, A. M., Nerlakanti, N., Patel, A. K., Agarwal, N., Teer, J. K., Dhillon, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46064-4 · Cited by 32
Kryza, T., Bock, N., Lovell, S., Rockstroh, A., Lehman, M., Lesner, A., Panchadsaram, J., Silva, L. M., Srinivasan, S., Snell, C. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12587 · Cited by 32
BRCA2 gene mutation and prostate cancer risk
Junejo, N. N., & Alkhateeb, S. S. (2020) · Saudi Medical Journal · doi:10.15537/smj.2020.1.24759 · Cited by 37
Nientiedt, C., Budczies, J., Endris, V., Kirchner, M., Schwab, C., Jurcic, C., Behnisch, R., Hoveida, S., Lantwin, P., Kaczorowski, A., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.024 · Cited by 32
Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer
Xu, L., Zhao, B., Butler, W., Xu, H., Song, N., Chen, X., Hauck, J. S., Gao, X., Zhang, H., Groth, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02155-z · Cited by 32
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou-Kheir, W. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.15 · Cited by 35
The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
Storck, W. K., May, A. M., Westbrook, T. C., Duan, Z., Morrissey, C. M., Yates, J. A., & Alumkal, J. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.926585 · Cited by 32
Schade, A. E., Kuzmickas, R., Rodriguez, C. L., Mattioli, K., Enos, M., Gardner, A., & Cichowski, K. M. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002038 · Cited by 34
Liu, W., Bai, X., Liu, Y., Wang, W., Han, J., Wang, Q., Xu, Y., Zhang, C., Zhang, S., Li, X., et al. (2015) · Scientific Reports · doi:10.1038/srep13192 · Cited by 32
Li, J., Karki, A., Hodges, K. B., Ahmad, N., Zoubeidi, A., Strebhardt, K., Ratliff, T. L., Konieczny, S. F., & Liu, X. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00825-15 · Cited by 32
Androgen receptor epigenetics.
Cai, C., Yuan, X., & Balk, S. P. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-4683.2013.09.02 · Cited by 32
Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Chen, J., Herlong, H. F., Stroehlein, J. R., & Mishra, L. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160122120008 · Cited by 33
Zhao, D., Ma, G., XiaoLin, Z., He, Y., Li, M., Han, X., Fu, L., Dong, X.-Y., Nagy, T., Zhao, Q., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719377 · Cited by 32
Lee, M., Lee, J., Kim, Y., & Lee, H. (2019) · The Prostate · doi:10.1002/pros.23837 · Cited by 32
PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
Miller, K. A., Degan, S. E., Wang, Y., Cohen, J., Ku, S., Goodrich, D. W., & Gelman, I. H. (2023) · Oncogene · doi:10.1038/s41388-023-02875-4 · Cited by 31
Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
Allen, E. M. V., Foye, A., Wagle, N., Kim, W., Carter, S. L., McKenna, A., Simko, J. P., Garraway, L. A., & Febbo, P. G. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.37 · Cited by 31
Somatic alterations and dysregulation of epigenetic modifiers in cancers
Aumann, S., & Abdel-Wahab, O. I. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.004 · Cited by 31
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer
Lefort, K., Ostano, P., Grand, M. M., Calpini, V., Scatolini, M., Farsetti, A., Dotto, G. P., & Chiorino, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10333 · Cited by 31
Treatment strategies for DNA repair-deficient prostate cancer
Teply, B. A., & Antonarakis, E. S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1338138 · Cited by 31
Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer
Voelkel‐Johnson, C., Norris, J. S., & White‐Gilbertson, S. J. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.014 · Cited by 31
Feng, H., Tong, H., Yan, J., He, M. Y., Chen, W., & Wang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01439 · Cited by 31
Wang, Y., Wang, J., Yan, K., Lin, J., Zheng, Z., & Bi, J. (2020) · PeerJ · doi:10.7717/peerj.8786 · Cited by 31
Aberrant Activity of Histone–Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis
Poręba, E., Leśniewicz, K., & Durzyńska, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249340 · Cited by 31
Belluti, S., Semeghini, V., Rigillo, G., Ronzio, M., Benati, D., Torricelli, F., Bonetti, L. R., Carnevale, G., Grisendi, G., Ciarrocchi, A., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02166-4 · Cited by 32
Redox-dependent internalization of the purinergic P2Y 6 receptor limits colitis progression
Nishiyama, K., Nishimura, A., Shimoda, K., Tanaka, T., Kato, Y., Shibata, T., TANAKA, H. L., Kurose, H., Azuma, Y., Ihara, H., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj0644 · Cited by 31
Lin, C., Wang, B., Fu, Y., Huo, C., Wang, Y., Chen, B., Liu, W., Tseng, J., Jiang, S. S., Sie, Z., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.764 · Cited by 31
Prostate Cancer Genetics: A Review.
Wallis, C. J. D., & Nam, R. K. (2015) · PubMed Central · Cited by 31
Bromodomain-containing proteins in prostate cancer
Urbanucci, A., & Mills, I. G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.007 · Cited by 31
PTEN loss and activation of K‐RAS and β‐catenin cooperate to accelerate prostate tumourigenesis
Jefferies, M. T., Cox, A. C., Shorning, B. Y., Méniel, V. S., Griffiths, D. F. R., Kynaston, H., Smalley, M. J., & Clarke, A. R. (2017) · The Journal of Pathology · doi:10.1002/path.4977 · Cited by 33
Lin, X., Gu, Y. J., Kapoor, A., Wei, F., Aziz, T., Ojo, D., Jiang, Y., Bonert, M., Shayegan, B., Yang, H., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.06.006 · Cited by 31
Xu, X. J., Ge, R., Li, L., Wang, J., Lu, X., Xue, S., Chen, X., Li, Z., & Bian, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.031 · Cited by 31
Increased KIF4A expression is a potential prognostic factor in prostate cancer
Gao, H., Chen, X., Cai, Q., Shang, Z., & Niu, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8322 · Cited by 31
NOX2 oxidase expressed in endosomes promotes cell proliferation and prostate tumour development
Harrison, I. P., Vinh, A., Johnson, I. R. D., Luong, R., Drummond, G. R., Sobey, C. G., Tiganis, T., Williams, E. D., O’Leary, J. J., Brooks, D. A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26237 · Cited by 31
Takayama, K., Suzuki, Y., Yamamoto, S., Obinata, D., Takahashi, S., & Inoue, S. (2019) · Endocrinology · doi:10.1210/en.2018-00923 · Cited by 31
Chaturvedi, A. P., & Dehm, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_15 · Cited by 32
Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy
Chen, M., Nowak, D. G., & Trotman, L. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3680 · Cited by 30
Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini, C., Zanardi, E., Vallome, G., Cavo, A., Cerbone, L., Meglio, A. D., Fabbroni, C., Latocca, M. M., Rizzo, F., Messina, C. G. M., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.009 · Cited by 30
Sharma, A., Jiang, C., & De, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky271 · Cited by 30
Scimeca, M., Urbano, N., Bonfiglio, R., Mapelli, S. N., Catapano, C. V., Carbone, G. M., Ciuffa, S., Tavolozza, M., Schillaci, O., Mauriello, A., et al. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/9840962 · Cited by 30
Budka, J. A., Ferris, M. W., Capone, M. J., & Hollenhorst, P. C. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.182 · Cited by 30
Das, S. K., Kegelman, T. P., Pradhan, A. K., Shen, X., Bhoopathi, P., Talukdar, S., Maji, S., Sarkar, D., Emdad, L., & Fisher, P. B. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1019 · Cited by 30
Braadland, P. R., Ramberg, H., Grytli, H. H., Urbanucci, A., Nielsen, H. K., Guldvik, I. J., Engedal, A., Ketola, K., Wang, W., Svindland, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0605 · Cited by 30
SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription
Liu, Y., Jin, M., Park, S. J., Seo, S., & Jeong, K. W. (2020) · Cancers · doi:10.3390/cancers12071736 · Cited by 30
Weitz, P., Wang, Y., Kartasalo, K., Egevad, L., Lindberg, J., Grönberg, H., Eklund, M., & Rantalainen, M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac343 · Cited by 30
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
